Abstract: The present invention provides novel methods of inhibiting bone loss comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I ##STR1## wherein R.sup.1 and R.sup.2 may be the same or different provided that, when R.sup.1 and R.sup.2 are the same, each is a methyl or ethyl group, and, when R.sup.1 and R.sup.2 are different, one of them is a methyl or ethyl group and the other is a hydrogen or a benzyl group; or a pharmaceutically acceptable salt thereof; together with or in combination with parathyroid hormone.

Abstract: The present invention relates to certain compounds of the formula (I) the racemic-enantiomeric mixtures and optical isomers of said compounds, prodrugs thereof and the pharmaceutically acceptable salts, depicted below, which are .beta.-adrenergic receptor agonists and accordingly have utility as, inter alia, hypoglycemic and antiobesity agents. The invention also relates to methods of use for the compounds and to compositions containing them. The compounds of the present invention also possess utility for increasing lean meat deposition and/or improving the lean meat to fat ratio in animals, e.g., ungulate animals, companion animals, especially dogs, and poultry. The compounds of formula (I) have the following structure ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined in the specification.

Abstract: The present invention relates to an apparatus for spectrophotometric analysis of a material in a container by reflectance of a beam applied to the material through an aperture in a primary mask. A restricted beam resulting from the primary mask is applied through a port in an opaque secondary mask to the material. The restricted beam is wholly within the port and radiation reflected from the material passes through the port to detectors for analysis. The secondary mask defines by its port an area on the base of the container through which the restricted beam is applied to the material and is not subjected to spurious reflections and refractions otherwise created by the container between its base and side wall. The container may be spaced from the secondary mask and inclined relative thereto so that the secondary mask shields the top and bottom ends of the container.

Abstract: Compound of formula (1) and their pharmaceutically acceptable salts wherein A1,A2,R1, R2,R3,R4,X are as defined in the specification have excellent bradykinin antagonistic activity.

Abstract: This invention relates to the field of Pasteurella haemolytica vaccines. More particularly, the invention relates to a bacterin-toxoid vaccine capable of inducing immunity in bovine species in one dose against Pasteurella haemolytica Type A-1 infection comprising Pasteurella haemolytica derived leukotoxoid, capsular antigen, soluble antigens and cells, methods to make the vaccine and methods of vaccinating bovine animals.

Abstract: Tablets of increased strength are manufactured by combining and compressing a meltable binder, excipients and a pharmaceutically active agent into a tablet, melting the binder in the tablet, and then solidifying the binder.

Abstract: The invention relates to a compound of the formula I ##STR1## wherein R.sup.1 is a cyclic imide group and X, Y, R.sup.2, and R.sup.3 are as defined herein. The invention further relates to pharmaceutical compositions containing, and methods of using, compounds of the formula I. Compounds of the formula I are useful in the treatment of diseases related to the production of matrix metalloproteinases and tumor necrosis factor.

Abstract: The present invention relates to diazabicyclic compounds and, specifically, to compounds of the formula ##STR1## wherein A, G, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are as defined in the specification. The compounds of formula I are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.

Abstract: A compound of the formula ##STR1## or a pharmaceutically acceptable salt thereof; W is hydrogen, (C.sub.1 -C.sub.6)alkyl optionally substituted with from one to three fluorine atoms, --S(O).sub.v --(C.sub.1 -C.sub.6) alkyl wherein v is zero, one or two, halo, benzyloxy or (C.sub.1 -C.sub.6)alkoxy optionally substituted with from one to three fluorine atoms;R.sup.1 is a 4, 5 or 6 membered heterocyclic ring containing from one to three heteroatoms selected from oxygen, nitrogen and sulfur, wherein said heterocyclic ring contains from zero to three double bonds and is optionally substituted with one or two substituents independently selected from (C.sub.1 -C.sub.6) alkyl optionally substituted with from one to three fluorine atoms and (C.sub.1 -C.sub.6) alkoxy optionally substituted with from one to three fluorine atoms;R.sup.2 is hydrogen or --CO.sub.2 (C.sub.1 -C.sub.10)alkyl;R.sup.

Abstract: Quinuclidine derivatives of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein m, P, Z, Y, R.sup.1, R.sup.2 and R.sup.3 are as defined below. The compounds are substance P antagonists and, therefore, are useful in treating gastrointestinal disorders, central nervous system disorders, inflammatory diseases, pain and migraine.

Abstract: This invention relates to compounds of formula (IA), (IB), (IC) or (ID), wherein m, X, Z, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.14 and the dotted lines are as defined below, their pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of using them to treat Alzheimer's disease, age-associated memory impairment, Parkinson's disease and other central nervous system disorders. The claimed compounds have the ability to enhance the release of neurotransmitters such as acetylcholine, dopamine and serotonin.

Abstract: The present invention is directed to compounds of formula (I), and the pharmaceutically acceptable acid addition salts thereof, wherein R is selected from the group consisting of F,--CF.sub.3, --OCH.sub.3, --O(C.sub.1)alkyl substituted with 1 to 3 fluoro atoms. --O(C.sub.2) substituted with 1 to 5 fluoro atoms, and --O(C.sub.3)alkyl substituted with 1 to 7 fluoro atoms. The compounds of formula (I) are useful in the treatment of stroke, traumatic brain injury and central nervous system degenerative diseases.

Abstract: This invention provides a method for treating a condition or disease selected from endometriosis, obesity, benign prostatic hypertrophy and prostatic carcinoma in mammals which comprises administering to said mammal an amount of droloxifene or a pharmaceutically acceptable salt thereof which is effective in treating said condition or disease.

Abstract: Compounds of formula (I), wherein A represents N or CH; R.sup.1 and R.sup.2 independently represent C.sup.1-4 alkyl, halo or CF.sub.3 ; R.sup.3 represents C.sub.1-4 alkyl (optionally substituted), C.sub.3-7 cycloalkyl, CF.sub.3 or aryl; R.sup.4 represents H, C.sub.3-7 cycloalkyl or C.sub.1-6 alkyl (optionally substituted); and their pharmaceutically acceptable derivatives; are useful in the treatment of, inter alia, neurodogenerative disorders.

Abstract: Substituted pydrido?1,2-a!pyrazines of general formula I wherein Ar and Ar.sup.1 represent various carbocyclic and heterocyclic aromatic rings; A represents O, S, SO, SO.sub.2, C.dbd.O, CHOH, or --(CR.sup.3 R.sup.4) and n is 0-2 as well as precursors thereto are ligands for dopamine receptor subtypes within the body and are therefore useful in the treatment of disorders of the dopamine system.

Abstract: Compounds of formula (I), wherein A, B, D, E, and F are each independently nitrogen or carbon; R.sub.1 is hydrogen, C.sub.1 to C.sub.6 alky, --(CH.sub.2).sub.n R.sub.7, or C.sub.1 to C.sub.3 alkyl-aryl; R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are each independently hydrogen, C.sub.1 to C.sub.6 alkyl, aryl, C.sub.1 to C.sub.3 alkyl-aryl, halogen, cyano, nitro, --(CH.sub.2).sub.m NR.sub.8 R.sub.9, --(CH.sub.2).sub.m OR.sub.9, --SR.sub.9, --SO.sub.2 NR.sub.8 R.sub.9, --(CH.sub.2).sub.m NR.sub.8 SO.sub.2 R.sub.9, --(CH.sub.2).sub.m NR.sub.8 CO.sub.2 R.sub.9, --(CH.sub.2 .sub.m NR.sub.8 COR.sub.9, --(CH.sub.2).sub.m CONR.sub.7 R.sub.9, or --(CH.sub.2).sub.m CO.sub.2 R.sub.9 ; R.sub.2 and R.sub.3, R.sub.3 and R.sub.4, R.sub.4 and R.sub.5, and R.sub.5 and R.sub.6 may be taken together to form a 5- to 7-membered alkyl ring, a 6-membered aryl ring, a 5- to 7-membered heteroalkyl ring, having 1 heteroatom of N, O, or S, or a 5- to 6-membered heteroaryl ring having 1 or 2 heteroatoms of N, O, or S; R.sub.

Abstract: A compound of the formula (IV) ##STR1## and a process for preparing the compound of formula (IV). Also disclosed is a process for preparing C-16-demethylrapamycin and C-39-demethylrapamycin. The process of this invention comprises fermenting Actinoplanes sp. ATCC 63771 in the presence of rapamycin and isolating the products produced thereby.

Abstract: A non-lymphoid continuous cell line adapted for propagation of avian coccidia is provided. This cell line is useful for the production of vaccine antigenes for prophylactic treatment of poultry, particularly in a novel vaccine for coccidia.

Abstract: A process for preparing a compound of formula (I): ##STR1## wherein R is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl or benzyl, and wherein the phenyl moiety of said benzyl group is optionally substituted with one or two substituents each independently selected from halo, nitro, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, amino and trifluoromethyl, which comprises treating a solution of a compound of formula (II): ##STR2## wherein R is as defined for formula (I), and a halonitromethane in a first organic solvent, with a quaternary ammonium fluoride of formula (III):R.sup.1 R.sup.2 R.sup.3 F.sup.4 N.sup.+ F.sup.- (III)wherein R.sup.1,R.sup.2,R.sup.3 and R.sup.4 are each independently selected from C.sub.1 -C.sub.8 alkyl and benzyl, optionally in solution in a second organic solvent.